Tyme Ticks On With Mid-Stage Development Of A Broad Cancer Therapy
The small biotech presented positive interim data from a Phase II trial testing its lead candidate SM-88 in prostate cancer at ESMO and is gearing up to initiate a trial in pancreatice cancer.
You may also be interested in...
The JP Morgan conference uptick in biopharma deal-making has begun with more than 20 deals announced this week, including the latest Bayer/Evotec partnership and Pfizer’s cancer tie-up with eFFECTOR.
COVID-19 disruptions, less favorable currency and the shadow of drug price reform could mean more headwinds for pharma during this S&E period after a strong Q2.
Congress is considering legislation that would reverse some of the Trump administration's friendly corporate tax policies, presenting another challenge to the biopharmaceutical industry.